GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Degree of Operating Leverage

Cutia Therapeutics (HKSE:02487) Degree of Operating Leverage : -0.80 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Cutia Therapeutics's Degree of Operating Leverage for the quarter that ended in Dec. 2024 was -0.80. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Cutia Therapeutics's Degree of Operating Leverage or its related term are showing as below:

HKSE:02487's Degree of Operating Leverage is ranked better than
69.24% of 881 companies
in the Biotechnology industry
Industry Median: -0.02 vs HKSE:02487: -0.80

Cutia Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Cutia Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Degree of Operating Leverage Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
- 0.14 0.23 -0.80

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Degree of Operating Leverage Get a 7-Day Free Trial 0.14 0.10 0.23 -0.22 -0.80

Competitive Comparison of Cutia Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Cutia Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Degree of Operating Leverage falls into.


;
;

Cutia Therapeutics Degree of Operating Leverage Calculation

Cutia Therapeutics's Degree of Operating Leverage for the quarter that ended in Dec. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -451.573 (Dec. 2024) / -2143.02 (Dec. 2023) - 1 )/( 298.537 (Dec. 2024) / 150.529 (Dec. 2023) - 1 )
=-0.7893/0.9833
=-0.80***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Cutia Therapeutics  (HKSE:02487) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Cutia Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Executives
Zhang Lele 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Yf Dermatology Limited 2101 Beneficial owner
Yunfeng Capital Limited 2102 Investment manager
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines